Choice of first-line therapy in metastatic melanoma

被引：13

作者：

Gibney, Geoffrey T. ^{[1
]}

Atkins, Michael B. ^{[1
]}

机构：

[1] MedStar Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA

来源：

CANCER | 2019年 / 125卷 / 05期

关键词：

OPEN-LABEL; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; DABRAFENIB; SURVIVAL; EFFICACY; PHASE-3; COMBINATION; MULTICENTER;

D O I：

10.1002/cncr.31774

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Anti-PD-1, alone or in combination with anti-CTLA-4, and targeted BRAF therapies comprise the current first-line systemic therapies for patients with metastatic melanoma. The decision on treatment choice is based on BRAF status, disease status, toxicity, efficacy profiles, comorbidities, and patient preferences.

引用

页码：666 / 669

页数：4

共 22 条

[1]

[Anonymous], 2017, J CLIN ONCOL S

[2] Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial [J].

Ascierto, Paolo A. ;

McArthur, Grant A. ;

Dreno, Brigitte ;

Atkinson, Victoria ;

Liszkay, Gabrielle ;

Di Giacomo, Anna Maria ;

Mandala, Mario ;

Demidov, Lev ;

Stroyakovskiy, Daniil ;

Thomas, Luc ;

de la Cruz-Merino, Luis ;

Dutriaux, Caroline ;

Garbe, Claus ;

Yan, Yibing ;

Wongchenko, Matthew ;

Chang, Ilsung ;

Hsu, Jessie J. ;

Koralek, Daniel O. ;

Rooney, Isabelle ;

Ribas, Antoni ;

Larkin, James .

LANCET ONCOLOGY, 2016, 17 (09) :1248-1260

[3] Off treatment survival (OTS) in patients (pts) with advanced melanoma after anti-PD1 therapy. [J].

Christiansen, Shelly Ann ;

Swoboda, David ;

Gardner, Kellie ;

Rapisuwon, Suthee ;

Atkins, Michael B. ;

Gibney, Geoffrey Thomas .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[4] Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis [J].

D'Angelo, Sandra P. ;

Larkin, James ;

Sosman, Jeffrey A. ;

Lebbe, Celeste ;

Brady, Benjamin ;

Neyns, Bart ;

Schmidt, Henrik ;

Hassel, Jessica C. ;

Hodi, F. Stephen ;

Lorigan, Paul ;

Savage, Kerry J. ;

Miller, Wilson H., Jr. ;

Mohr, Peter ;

Marquez-Rodas, Ivan ;

Charles, Julie ;

Kaatz, Martin ;

Sznol, Mario ;

Weber, Jeffrey S. ;

Shoushtari, Alexander N. ;

Ruisi, Mary ;

Jiang, Joel ;

Wolchok, Jedd D. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (02) :226-+

[5] Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial [J].

Davies, Michael A. ;

Saiag, Philippe ;

Robert, Caroline ;

Grob, Jean-Jacques ;

Flaherty, Keith T. ;

Arance, Ana ;

Chiarion-Sileni, Vanna ;

Thomas, Luc ;

Lesimple, Thierry ;

Mortier, Laurent ;

Moschos, Stergios J. ;

Hogg, David ;

Marquez-Rodas, Ivan ;

Del Vecchio, Michele ;

Lebbe, Celeste ;

Meyer, Nicolas ;

Zhang, Ying ;

Huang, Yingjie ;

Mookerjee, Bijoyesh ;

Long, Georgina V. .

LANCET ONCOLOGY, 2017, 18 (07) :863-873

[6] Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial [J].

Dummer, Reinhard ;

Ascierto, Paolo A. ;

Gogas, Helen J. ;

Arance, Ana ;

Mandala, Mario ;

Liszkay, Gabriella ;

Garbe, Claus ;

Schadendorf, Dirk ;

Krajsova, Ivana ;

Gutzmer, Ralf ;

Chiarion-Sileni, Vanna ;

Dutriaux, Caroline ;

de Groot, Jan Willem B. ;

Yamazaki, Naoya ;

Loquai, Carmen ;

Moutouh-de Parseval, Laure A. ;

Pickard, Michael D. ;

Sandor, Victor ;

Robert, Caroline ;

Flaherty, Keith T. .

LANCET ONCOLOGY, 2018, 19 (05) :603-615

[7] Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial [J].

Goldberg, Sarah B. ;

Gettinger, Scott N. ;

Mahajan, Amit ;

Chiang, Anne C. ;

Herbst, Roy S. ;

Sznol, Mario ;

Tsiouris, Apostolos John ;

Cohen, Justine ;

Vortmeyer, Alexander ;

Jilaveanu, Lucia ;

Yu, James ;

Hegde, Upendra ;

Speaker, Stephanie ;

Madura, Matthew ;

Ralabate, Amanda ;

Rivera, Angel ;

Rowen, Elin ;

Gerrish, Heather ;

Yao, Xiaopan ;

Chiang, Veronica ;

Kluger, Harriet M. .

LANCET ONCOLOGY, 2016, 17 (07) :976-983

[8]

Grob JJ, 2017, ANN ONCOL, V28

[9] Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review [J].

Heppt, Markus V. ;

Steeb, Theresa ;

Schlager, Justin Gabriel ;

Rosumeck, Stefanie ;

Dressler, Corinna ;

Ruzicka, Thomas ;

Nast, Alexander ;

Berking, Carola .

CANCER TREATMENT REVIEWS, 2017, 60 :44-52

[10]

Hodi F.S., 2016, Cancer Research, V76, pCT001, DOI [10.1158/1538-7445.AM2016-CT001, DOI 10.1158/1538-7445.AM2016-CT001, 10.1158/1538-7445.am2016-ct001]

← 1 2 3 →